Patent ID: 11866511
Assignee: TIGATX, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 0:
1. An engineered antibody that comprises:
(a) an IgG variable region that comprises:
(i) a heavy chain variable domain that comprises:
a complementarity determining region 1 (CDR1) comprising an amino acid sequence GSSFTGYN (SEQ ID NO: 14),
a complementarity determining region 2 (CDR2) comprising an amino acid sequence IDPYYGGT (SEQ ID NO: 15), and
a complementarity determining region 3 (CDR3) comprising an amino acid sequence VSGMEY (SEQ ID NO: 16), and

(ii) a light chain variable domain that comprises:
a complementarity determining region 1 (CDR1) comprising an amino acid sequence QSLVHRNGNTY (SEQ ID NO: 17),
a complementarity determining region 2 (CDR2) comprising an amino acid sequence KVS (SEQ ID NO: 18), and
a complementarity determining region 3 (CDR3) comprising an amino acid sequence of QSTHVPPLT (SEQ ID NO: 19); and

(b) a heavy chain constant region that comprises an IgA CH1 heavy chain constant domain, an IgA CH2 heavy chain constant domain, an IgA hinge domain, and an IgA CH3 heavy chain constant domain, wherein the heavy chain constant region comprises:
(ii) an amino acid substitution at N337 according to Bur scheme corresponding to N207 of SEQ ID NO: 11; 1338 according to Bur scheme corresponding to 1208 of SEQ ID NO: 11; and T339 according to Bur scheme corresponding to T209 of SEQ ID NO: 11,
(ii) an amino acid substitution at N166 according to Bur scheme corresponding to N49 of SEQ ID NO: 11,
(iii) an amino acid substitution at P221 according to Bur scheme corresponding to P104 of SEQ ID NO: 11,
(iv) an amino acid substitution at C311 according to Bur scheme corresponding to C181 of SEQ ID NO: 11,
(v) a deletion of amino acid C471 according to Bur scheme corresponding to C341 of SEQ ID NO: 11,
(vi) a deletion of amino acid Y472 according to Bur scheme corresponding to Y342 of SEQ ID NO: 11, or
(vii) a combination thereof.